Top advances of the year: Acute myeloid leukemia

• DOI: 10.1002/cncr.35834
• Publication Date: 2025-04-07T21:32:58Z
• Authors: Rahul K. Thakur; Eunice S. Wang

This article highlights key advances in the treatment of acute myeloid leukemia, specifically menin inhibitors for relapsed disease and retinoic acid/arsenic‐based therapy for high‐risk acute promyelocytic leukemia. Validation of mutational profiles and measurable residual disease methodology as key predictors of treatment outcomes support a personalized, precision‐based treatment approach for acute myeloid leukemia in the future.